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Abstract 
Background: Environmental exposures underlie to a great extent the causation of 
Parkinson's disease. We aimed to summarise the environmental risk factors that have 
been studied for potential association with Parkinson’s disease, assess the presence   
of diverse biases, and identify the risk factors with the strongest support. 
Methods: We searched PubMed from inception to April 16, 2015, to identify 
systematic reviews and meta-analyses of observational studies that examined 
associations between environmental factors and Parkinson’s disease. For each meta-
analysis we estimated the summary effect size by use of random-effects and fixed-
effects models, the 95% confidence interval and the 95% prediction interval. We 
estimated the between-study heterogeneity expressed by I², evidence of small-study 
effects and evidence of excess significance bias. 
Results: Overall, 66 unique meta-analyses including primary studies of different risk 
factors and Parkinson’s disease were examined, covering diverse biomarkers, dietary 
factors, drugs, medical history or comorbid diseases, exposure to toxic environmental 
agents and habits. 34 of 66 meta-analyses had results that were significant at p-values 
<0.05 and 20 at p-values <0.001 by random effects. Evidence for an association was 
highly suggestive (more than 1000 cases, p<10-6 by random effects, and largest study 
with 95% CI excluding the null) for anxiety or depression, beta-blockers, head injury, 
physical activity, serum uric acid, and smoking. However, all of them had high 
heterogeneity and/or some hints for bias. 
Conclusion: Many environmental factors have substantial evidence of association 
with Parkinson’s disease, but several, perhaps most, of them may reflect reverse 
causation, residual confounding, information bias, sponsor conflicts or other caveats. 
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Introduction 
Parkinson’s disease (PD) is the second most common neurodegenerative disorder, 
after Alzheimer’s disease.1 The prevalence of PD is rising steadily with age; reaching 
1,903 per 100,000 in older than age 802 and is expected to impose an increasing social 
and economic burden on societies as population ages.
1
 Approximately 630,000 people 
in the United States had been diagnosed with PD in 2010, with diagnosed prevalence 
likely to double by 2040.3 In USA, the economic burden of PD exceeds $14.4 billion 
in 2010 (approximately $22,800 per patient) and it is projected to grow substantially 
over the next few decades.3  
Major gene mutations cause only a small proportion of all cases and about 90% of 
cases are sporadic.
4
 To our knowledge, there is no previous attempt to summarize the 
evidence from existing meta-analyses on non-genetic risk factors for Parkinson’s 
disease. We performed an umbrella review of the evidence across existing systematic 
reviews and meta-analyses of observational studies. Our aim is to provide an 
overview of the range and validity of the reported associations of diverse 
environmental risk factors with PD by evaluating whether there is evidence for biases 
in this literature. Finally we pinpoint which of the previously studied associations that 
have been synthesized with meta-analyses have the strongest evidence for association. 
 
Methods 
Search strategy and eligibility criteria 
We conducted an umbrella review, a systematic collection and evaluation of multiple 
systematic reviews and meta-analyses performed on a specific research topic.5 The 
Page 4 of 40
John Wiley & Sons
Movement Disorders
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
For Peer Review
5 
 
methods of the umbrella review are standardized and follow exactly the same 
principles as a previous umbrella review on risk factors for multiple sclerosis.6 We 
systematically searched PubMed from inception to April 16, 2015 to identify 
systematic reviews and meta-analyses of observational studies examining associations 
of environmental (non-genetic) factors and biomarkers with PD. The search strategy 
used the keywords Parkinson* AND (“systematic review” OR meta-analysis). The 
full text of potentially eligible articles was scrutinized independently by two 
investigators (VB, LB). We excluded meta-analyses that investigated the association 
between genetic markers and risk for PD as these factors have been examined 
elsewhere.7 When a study included meta-analyses of both genetic and environmental 
risk factors, we only extracted information on the latter. Moreover, meta-analyses 
with an outcome related to progression of PD or severity of symptoms were excluded. 
We also excluded meta-analyses examining PD as a risk factor for other medical 
conditions. We did not apply any language restrictions. When more than one meta-
analyses on the same research question was eligible, the meta-analysis with the largest 
number of component studies with data on individual studies’ effect sizes was 
retained for the main analyses. We kept a record of other meta-analyses focused on 
the same risk factor. 
Data extraction 
Data extraction was performed independently by two investigators (VB, LB), and in 
case of discrepancies the final decision was that of a third investigator (EE). From 
each eligible article, we recorded the first author, journal, year of publication, the 
examined risk factors and the number of studies considered. If a quantitative synthesis 
was done, we also extracted the study-specific relative risk estimates (mean 
difference, risk ratio, odds ratio, hazard ratio or incident risk ratio) along with the 
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corresponding CI and the number of cases and controls in each study for each risk 
factor. Furthermore, we recorded the study design of individual studies. We recorded 
whether the published meta-analyses applied any criteria to evaluate the quality of the 
included observational studies; when such an appraisal was performed, we extracted 
the information on this qualitative assessment. Whenever the studies used several 
control groups, we extracted the data considering the healthy controls as control 
group. 
Statistical analysis 
For each meta-analysis, we estimated the summary effect size and its 95% CI using 
both fixed-effects and random-effects models.
8,9
 We also estimated the 95% 
prediction interval, which further accounts for between-study heterogeneity and 
evaluates the uncertainty for the effect that would be expected in a new study 
addressing that same association.10,11 For the largest study of each meta-analysis, we 
estimated the SE of the effect size and we examined whether the SE was less than 0.1. 
In a study with SE of less than 0.1, the difference between the effect estimate and the 
upper or lower 95% confidence interval is less than 0.2 (i.e. this uncertainty is less 
than what is considered a small effect size).  
In case of meta-analyses with continuous data, the effect estimate was transformed to 
an odds ratio with an established formula.12 Between-study heterogeneity was 
assessed via the I2 metric.13 I2 ranges between 0% and 100% and is the ratio of 
between-study variance over the sum of the within- and between-study variances.
14
 
Values exceeding 50% or 75% are usually considered to represent large or very large 
heterogeneity, respectively. The 95% CI of I2 estimates can be wide when there are 
few studies.15 
Page 6 of 40
John Wiley & Sons
Movement Disorders
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
For Peer Review
7 
 
We evaluated whether there was evidence for small-study effects (i.e. whether smaller 
studies tend to give substantially larger estimates of effect size compared with larger 
studies)16 using the regression asymmetry test proposed by Egger and colleagues.17 A 
P value less than 0.1 with more conservative effect in larger studies judged to be 
evidence for small-study effects. 
We applied the excess statistical significance test, which evaluates whether the 
observed (O) number of studies with nominally statistically significant results 
(“positive” studies, P<0.05) is larger than their expected (E) number.18 E is calculated 
in each meta-analysis by the sum of the statistical power estimates for each 
component study. The true effect size for any meta-analysis is not known. We 
estimated the power of each component study using the effect size of the largest study 
(smallest SE) in a meta-analysis.19 The power of each study was calculated using a 
non-central t distribution.20 Excess statistical significance for single meta-analyses 
was claimed at two-sided P<0.10 with O>E as previously proposed.18 
For the meta-analyses
21
 on pesticides and well-water drinking, we used data from 
older meta-analyses
22,23
, because the largest one did not adequately report the data 
needed to perform our analyses. For the meta-analysis on diabetes mellitus, we 
extracted data from two different papers.24,25 The more recently published paper25 
reported data only from case-control studies and the older one24 included case-control 
and cohort studies, from which we kept cohort studies only and synthesized them with 
case-control studies from the recent paper. For two meta-analyses, pertaining to 
constipation23 and gout26, we were not able to assess small-study effects and to 
estimate the 95% prediction interval, because only 2 observational studies were 
available for each meta-analysis. 
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Finally, we identified putative risk factors that had the strongest statistical support for 
association27,28 and no signals of high heterogeneity or bias. Specifically, we used the 
following categories: Highly convincing evidence required >1000 cases, highly 
statistically significant summary associations (p<10-6 by random effects), no evidence 
of small-study effects, no evidence of excess significance bias, 95% prediction 
interval not including the null and not large heterogeneity (I
2
<50%). Highly 
suggestive evidence required >1000 cases, highly statistically significant summary 
associations (p<10-6 by random effects) and largest study with 95% CI excluding the 
null. Suggestive evidence required only >1000 cases and p<0.001 by random effects. 
All other risk factors with nominally significant summary associations (p<0.05) were 
coined as having weak evidence. Non-significant associations were those with 
p>0.05. 
Even when evidence for association is convincing or highly suggestive, this still does 
not prove causation. Therefore, in the Discussion, we explore systematically all 
putative risk factors with strong or highly suggestive evidence for association in terms 
of alternative explanations besides a causal relationship (reverse causation, residual 
confounding, information bias, sponsor conflicts or other caveats).  
The statistical analysis and the power calculations were done with STATA version 
12.0. 
Role of the funding source 
There was no funding source for this study. All authors had full access to all the study 
data. The corresponding author had final responsibility for the decision to submit for 
publication. 
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Results 
Overall, 884 articles were searched and 32 articles were eligible (figure). The eligible 
papers were published between 2005 and 2015 (median, 2013; IQR, 2012-2014). 21 
articles were excluded in full text screening, because a larger meta-analysis was 
available. The aforementioned 21 articles examined smoking (n=9),
29–37
 pesticides 
(n=5),38–42 physical activity (n=2),43,44 coffee (n=3),35,45,46 farming (n=1)39, aspirin 
(n=1),47 bone mineral density (n=1),48 fat intake (n=1),49 ibuprofen (n=1),47 tea 
(n=1),45 and well water drinking (n=1)39. One article50 on body mass index was 
excluded due to inadequate data reporting. 
The 32 articles correspond to 66 unique meta-analyses, including 691 primary 
observational studies as a whole. The median number of studies per meta-analysis 
was 7 (IQR 5-11) and the median number of cases was 1405 (IQR 677-4899). The 66 
meta-analyses covered a wide range of risk factors categorized as biomarkers, dietary 
factors, drugs, exposure to toxic environmental agents, habits and medical history or 
comorbid diseases. The number of cases was greater than 1000 in 41 meta-analyses. 
All eligible meta-analyses used summary-level data from published literature and 
none of them had access to individual participant data. In 4 papers51–54 (7 meta-
analyses) the effect size was expressed in weighted mean difference, which we 
transformed to standardized mean difference and then to OR. In 2 papers55,56 (6 meta-
analyses) the summary effect size was expressed in standardized mean difference, 
which we transformed to OR. 
Thirteen articles used the Newcastle-Ottawa Scale to qualitatively assess the included 
primary studies. Details are presented in table 4. Another article24 assessed the 
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potential existence of bias in the case ascertainment and the selection bias. An 
additional article52 used the QUADAS-2 for this assessment. Taking into account the 
methodological assessment of the primary observational studies performed by the 
eligible papers, almost half of the primary studies presented low methodological 
quality and were of high risk for bias, according to Newcastle-Ottawa scale. 
34 (51%) of 66 meta-analyses reported effects that were significant at p values less 
than 0.05 under the random-effects model. 20 (30%) were significant at p values less 
than 0.001 under the random-effects model: physical activity, ibuprofen, head injury, 
dairy products intake, welding, anxiety or depression, beta-blockers, coffee drinking, 
constipation, smoking, pesticides, nigral volume loss, gout, serum uric acid, retinal 
nerve fiber layer thickness, calcium channel blockers, rural living, farming, alcohol 
drinking and bone mineral density in lumbar spine. In seven of these (dairy products 
intake, welding, anxiety or depression, coffee drinking, smoking, physical activity and 
ibuprofen) the 95% prediction interval rule for random-effects model did not include 
the null. The remaining meta-analyses of risk factors had prediction intervals that 
included the null value, showing that, although on average these putative risk factors 
are associated with PD, this might not always be the case in specific settings (table 1). 
The results of the largest study were more conservative than the summary result in 34 
(52%) meta-analyses (table 2). However, the largest study was typically not very large 
or substantially different in weight from other studies. In 21 meta-analyses, the SE of 
the largest study was less than 0.10 in a log OR scale (it was <0.20 in 51 meta-
analyses). 
38 (58%) meta-analyses had large heterogeneity estimates (I²≥50%) and 19 (29%) 
meta-analyses had very large heterogeneity estimates (I²>75%). Evidence for small-
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study effects was noted in 12 (18%) meta-analyses. These meta-analyses pertained to 
alcohol drinking, coffee drinking, energy intake, exposure to hydrocarbons, serum 
vitamin D, lutein intake, non-aspirin NSAIDs, organic solvents, pesticides, rural 
living, statins, and smoking. Assuming that the effect size in the largest study was the 
true effect, 35 (53%) of the 66 meta-analyses had a significant difference between the 
number of observed and expected positive studies (table 2). 
Of the 66 meta-analyses, 15 (23%) presented a significant association at P < 10-6. Six 
risk factors, which include anxiety or depression23, beta-blockers23, head injury57, 
serum uric acid55, physical activity58 and smoking23, presented highly suggestive 
evidence (>1000 cases, p<10
-6
 and largest study 95% CI excluding the null). 
However, all of these six risk factors had either large or very large heterogeneity 
(n=3), or prediction interval including the null value (n=3) or hints for small-study 
effects (n=1) and/or excess significance bias (n=2). 
An overall summary assessment of the strength of the evidence for association of 
putative risk factors with Parkinson’s disease is presented in table 3. 
 
Discussion 
We provide an overview and appraisal of environmental risk factors that have been 
associated with Parkinson’s disease. Overall, 66 risk factors have been studied for an 
association with the disease, including biomarkers, dietary factors, drugs, exposure to 
toxic environmental agents, habits and medical history or comorbid diseases. Several 
putative risk factors (head injury, anxiety or depression, beta-blockers, smoking, 
physical activity, serum uric acid) had very low p-values (<10-6) and an effect was 
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seen also in the largest study, but there was either large between-study heterogeneity 
and/or large uncertainty in the predictive interval and/or signals of bias. 
The majority of the examined meta-analyses had large heterogeneity and some had 
signals of small-study effects or/and excess significance. The applied Egger test is 
particularly difficult to interpret when between-study heterogeneity is large. 
Heterogeneity might often be a manifestation of bias in some studies of a meta-
analysis, but could also emerge from genuine differences across studies. Reasons for 
heterogeneity include the mixture of cohort studies and case-control studies in some 
of the meta-analyses, mixture of differences in exposure assessment, frequency of 
exposed in control groups, types of exposures and source of controls and differential 
response rates among cases and controls in the primary studies. The reported 
associations with disease need to be interpreted with caution, in particular for the 
meta-analyses in which the heterogeneity is large, the number of studies is relatively 
small, the largest study is more conservative than the summary effect, and small-study 
effects are evident. 
The observed inverse association between physical activity and PD is further 
supported by animal and human laboratory studies.59,60 In animal models exposed to 
toxic compounds like MPTP, forced physical activity, spared nigrostriatal 
dopaminergic terminals and attenuated movement abnormalities.59 In humans, 
physical exercise has been suggested to increase plasma urate and uric acid levels, 
which in turn have been associated with lower risk for Parkinson's disease.
58
 
However, an element of reverse causation cannot be totally excluded, since patients 
with pre-diagnosis of PD may exercise less because of the neurological 
dysfunction.61,62 Peripheral autonomic disorders in early stages of PD development 
may result in decreased cardiac chronotropic response during exercise and decrease 
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the level of physical activity. Also, for the association of physical activity with PD, 
we found evidence for excess significance.  
Among other putative risk factors, highly statistically significant associations were 
seen for increased risk with head injury, anxiety or depression, and beta-blockers, and 
for decreased risk with smoking and uric acid levels. In all of these factors, the largest 
study also showed a significant association signal. For smoking, the level of statistical 
significance for the association was extremely impressive (P = 1.30 × 10-37 by random 
effects), but there were strong signals for small-study effects and for excess 
significance. This suggests that the literature on this risk factor is probably subjected 
to selective reporting and other biases and the summary effects may be exaggerated. 
A small protective effect for smoking is nevertheless likely to exist. However, it has 
also been argued that much, if not all, of the association effect with smoking may be 
explained by various biases,63 rather than the neuroprotective role of nicotine.64 First, 
there may be lack of information regarding PD diagnoses in the death certificates and 
medical records of smokers (information bias). Second, there may be selective 
mortality of smokers from causes other than PD, constituting a form of selection bias 
due to competing risk. If smokers die earlier than non-smokers from causes unrelated 
to PD, smokers may be under-represented among prevalent PD patients. Third, 
individuals with PD may be less prone to smoke or more prone to quit (reverse 
causation).
63,65
 Last, smoking and PD may share common covariates (confounding) 
not accounted for in the primary studies. For example, genetic factors may be 
associated with both an increased risk of PD and a higher likelihood of abstaining 
from smoking.63 
Head trauma appeared to have a positive association with PD. According to a report 
by the International Collaboration on Mild Traumatic Brain Injury Prognosis,
66
 the 
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epidemiological evidence supports that mild traumatic brain injury is not associated 
with PD. Reverse causality may operate here, because head injury result from 
imbalance which is an early sign of PD.67,68 Likewise, depression is probably best 
seen as a prodromal symptom of PD rather than a risk factor, because an early stage 
of PD is characterized by loss of serotonigergic neuronal cells in the dorsal raphe 
nucleus.
69
  
Uric acid is thought to be a predictor of clinical progression of PD.70 In agreement to 
that, the meta-analysis of the two cohort studies examining the association of gout, a 
disease characterized by high levels of serum uric acid, with PD showed a robust 
protective effect, but more studies are needed to assess the reproducibility of these 
findings. However, the meta-analysis for serum urate, a metabolite of serum uric acid, 
presented a significant association supported by weak evidence. Furthermore, an 
association between dairy products and PD was supported by suggestive evidence. 
This association can be attributed to the reduction of serum uric acid levels, which 
was also supported by evidence from the Third National Health and Nutrition 
Examination Survey.
71
  
Degeneration of norepinephrine neurons in the locus coeruleus and deficits in 
norepinephrine are common findings in PD, which could be aggravated by use of beta 
blockers and lead to PD. This is probably depicted in the modest harmful effect of 
beta-blockers.72 
The association between pesticides and PD had a modest effect and was supported by 
suggestive evidence. However, there was evidence for large heterogeneity, small 
study effects and excess significance, leading to an inflated effect size. Furthermore, 
farming and rural living (proxies of exposure to pesticides) presented a significant 
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association with PD, but these associations were characterized by large heterogeneity 
and/or bias. Furthermore, organic solvents cause neurological problems and can 
hardly be considered specific dopaminergic toxins. The potential mechanism of action 
is damage of the basal ganglia. The mechanisms whereby these chemicals cause 
selective toxicity to these brain regions are not fully understood.73 Epidemiological 
studies on these exposures include different populations (occupational exposures or 
not), different thresholds of duration of exposure and different method of assessment 
of exposure (questionnaire or interview), so it is difficult to draw a safe conclusion. 
The large heterogeneity on the meta-analysis on pesticides and organic solvents could 
not be explained by the various chemical compounds that are included in these 
environmental exposures. The subgroup analysis performed per chemical compound 
either failed to show a statistically significant effect or preserved the large statistical 
heterogeneity, when the effect was significant.  
Two other evaluated factors, coffee and alcohol, showed impressive P values in their 
summary effects, suggesting a protective impact on PD. However, for both of them, 
the largest study showed no effect and there was evidence for small-study effects and 
excess significance. This suggests that the observed associations may be due to bias. 
However, on the basis of the protective effect of coffee in PD, adenosine receptor 
antagonists have been tested and there is some evidence that they improve 
parkinsonian symptoms in phase 2 clinical trials.
74,75
 An explanation for the observed 
inverse association between alcohol and PD may be residual confounding, possibly by 
smoking or coffee.64 Based on the Newcastle-Ottawa scale, two-thirds of the 
observational studies examining the association between alcohol and PD had low 
quality ratings. Moreover the finding that ibuprofen use, but not use of aspirin or other 
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NSAIDs, could be associated with lower PD risk suggests mechanisms other than a 
generic anti-inflammatory activity of NSAIDs.76 
PD diagnosis is based upon clinical criteria solely and symptoms arise after damage 
of at least 60% of dopaminergic substantia nigra cells.77 For that reason PD is quite 
often diagnosed in a stage of extensive damage, where neuroprotective agents fail to 
prevent any further damage.
78,79
 This is why the identification of a biomarker could be 
a breakthrough to help slow the progression of PD, by recognizing it at an earlier, 
preclinical even, stage. However none of the meta-analyses on biomarkers showed 
unequivocal evidence for association with PD. All meta-analyses about the wide 
spectrum of biomarker either imaging or measured in CSF, plasma or serum, have 
large heterogeneity and a small sample size.  
Our analysis has some caveats. Some of the caveats, pertaining to the interpretation of 
tests for statistical bias and the potentially effect inflation even in the largest studies, 
are applicable to all umbrella reviews of risk factors, as we have discussed on a 
previous umbrella review about risk factors for multiple sclerosis.
6
 We did not 
appraise the quality of the individual component primary studies, because this was 
beyond the scope of this umbrella review. This was the aim of the original systematic 
reviews and meta-analyses, which should include an assessment of study quality and 
whether the study should be included in the quantitative calculations. Indeed, some of 
the systematic reviews and meta-analyses applied the Newcastle-Ottawa scale to 
qualitatively appraise the observational studies, indicating almost half of these 
primary studies were of poor quality. Also, in our analysis we assessed only 
associations considered by meta-analyses of observational studies. Thus, we might 
miss other associations with adequate evidence that have not yet been assessed 
through meta-analytic approaches. Recently published cohort studies investigated the 
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exposure to extremely low frequency magnetic fields
80
, zolpidem intake
81
, and the 
existence of end-stage renal disease82 as risk factors for developing PD, but these 
factors have not been studied in a published meta-analysis and were not addressed in 
our analysis. Finally, while we focus on biases and other issues that may have led to 
false-positive associations, false-negatives cannot be excluded also, especially for 
associations where limited evidence from small studies is available.  
Acknowledging these caveats, our assessment maps the status of evidence on 
associations between environmental risk factors and risk for PD. A potential clinical 
implication of pinpointing the strong associations is the identification of high risk 
individuals for developing PD in order to run an organized screening program to 
detect preclinical stages of the disease. Such screening tests have already been 
proposed and include testing for non-motor prodromal symptoms i.e. hyposmia, 
constipation, depression, sleep disorders and apathy.79,83,84 Several associations have 
highly suggestive evidence, and fewer, if any, are likely to be causal, rather than 
confounded or the result of information biases or reverse causality. The mechanisms 
of several putative risk factors are not fully understood. Data from more studies and 
investigation of sources of heterogeneity are needed to better understand the 
association between these factors and PD. 
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Figure. Flow chart of literature search for systematic reviews and meta-analyses 
published from inception until April 16, 2015. 
 
 
 
 
 
889 articles reviewed 
by title screening 
83 articles reviewed by 
abstract screening 
32 eligible articles with 66 unique 
meta-analyses published until April 
16, 2015 
55 articles reviewed 
by full text 
806 articles were excluded 
290 were treatment studies  
199 were articles about genetic epidemiology 
163 had outcomes other than risk for Parkinson’s 
disease 
59 were editorials or narrative reviews 
32 were incidence or prevalence studies 
24 were methodological studies 
14 were articles about health economics 
25 were diagnostic or imaging studies 
28 articles were excluded 
12 had outcomes other than risk for Parkinson’s 
disease 
5 were editorials or narrative reviews 
6 were diagnostic or imaging studies 
2 were primary studies 
1 was treatment study 
1 was incidence or prevalence study 
1 was methodological study 
23 were excluded 
 21 were not the largest systematic reviews or
 meta-analyses investigating a risk factor 
  1 did not perform quantitative synthesis 
 1 had not adequate reporting of data 
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Table 1.Characteristics and quantitative synthesis of the 66 eligible meta-analyses of environmental risk factors for Parkinson’s disease. 
 
Reference Risk factor Level of 
comparison 
Total 
number of 
Cases/Contr
ols 
Number 
of 
primary 
studies 
Effec
t size 
Random effects 
summary effect 
size (95% CI) 
P random 95% PI Fixed effects 
summary effect 
size (95% CI) 
P fixed 
Habits 
Zhang, 
201485 
Alcohol 
intake 
High intake 
vs. Low intake 
9994/667662 33 RR 0.75 (0.66-0.85) 5.0 × 10-6 0.44-1.25 0.79 (0.73-0.86) 
 
4.8 × 10-9 
Noyce, 
201223 
Coffee 
drinking 
High intake 
vs. Low intake 
5801/723072 19 RR 0.67 (0.58-0.76) 3.4 × 10-9 0.45-1.00 0.72 (0.65-0.78) 
 
1.5 × 10-13 
Noyce, 
201223 
Smoking Exposed vs. 
Non exposed 
19537/10536
45 
67 RR 0.64 (0.60-0.69) 1.3 × 10-37 0.45-0.92 0.67 (0.65-0.70) 5.0 × 10-77 
Li, 201286 Tea drinking High intake 
vs. Low intake 
1418/4250 8 OR 0.86 (0.68-1.08) 0.197 0.45-1.62 0.85 (0.74-0.98) 0.025 
Yang, 201558 Physical 
activity 
High activity 
vs. Low 
activity 
1348/399959 5 HR 0.66 (0.57-0.78) 3.0 × 10-7 0.55-0.80 0.66 (0.57-0.78) 3.0 × 10-7 
Exposure to toxic environmental agents 
Mortimer, 
201287 
Manganese 
exposure 
Exposed vs. 
Non exposed 
1278/2762 3 RR 0.76 (0.41-1.42) 0.392 0.001-661 0.80 (0.59-1.08) 0.146 
Mortimer, 
201287 
Welding Yes vs. No 8198/572326 9 RR 0.86 (0.80-0.92) 3.0 × 10-5 0.79-0.94 0.86 (0.80-0.92) 3.0 × 10-5 
Palin, 201588 Hydrocarbon 
exposure 
Exposed vs. 
Non exposed 
4483/7179 14 OR 1.36 (1.13-1.63) 0.001 0.88-2.08 1.27 (1.12-1.46) 3.6 × 10-4 
Pezzoli, 
201321 
Farming Exposed vs. 
Non exposed 
9533/ 
2303116 
38 OR 1.30 (1.16- 1.46) 5.7 × 10-6 0.86-1.98 1.29 (1.19-1.39) 6.7 × 10-10 
Pezzoli, 
201321 
Organic 
solvents 
Exposed vs. 
Non exposed 
3811/163859 18 OR 1.22 (1.01-1.47) 0.036 0.72-2.08 1.12 (0.99-1.26) 0.052 
van der 
Mark, 201222 
Pesticides Exposed vs. 
Non exposed 
7151/292210 39 OR 1.62 (1.40-1.88) 1.1 × 10-10 0.81-3.23 1.52 (1.40-1.64) 5.9 × 10-26 
Pezzoli, Rural living Exposed vs. 4306/10009 31 OR 1.32 (1.18-1.48) 1.7 × 10-6 0.84-2.10 1.01 (0.99-1.02) 0.363 
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201321 Non exposed 
Noyce, 
201223 
Well water 
drinking 
Exposed vs. 
Non exposed 
5037/8144 28 RR 1.21 (1.05-1.40) 0.011 0.66-2.21 0.99 (0.95-1.04) 0.735 
Dietary factors 
Etminan, 
200589 
Vitamin C 
intake 
High intake 
vs. Low intake 
1247/9214 7 OR 1.06 (0.86- 1.30) 0.602 0.64-1.74 1.00 (0.87-1.16) 0.976 
Etminan, 
200589 
Vitamin E 
intake 
High intake 
vs. Low intake 
936/7230 7 OR 0.81 (0.67- 0.98) 0.028 0.63-1.04 0.81 (0.67-0.98) 0.028 
Jiang, 201490 Dairy 
products 
intake 
High intake 
vs. Low intake 
1083/310118 7 RR 1.40 (1.20- 1.63) 2.4 × 10-5 1.08-1.81 1.39 (1.21-1.61) 5.7 × 10-6 
Takeda, 
201491 
Lutein 
intake 
High intake 
vs. Low intake 
804/124720 4 OR 1.49 (0.83- 2.68) 0.179 0.12-18.65 1.15 (0.90-1.46) 0.267 
Takeda, 
201491 
Lycopene 
intake 
High intake 
vs. Low intake 
678/124288 3 OR 1.03 (0.64-1.65) 0.896 0.01-174 1.02 (0.79-1.31) 0.900 
Takeda, 
201491 
Vitamin A 
intake 
High intake 
vs. Low intake 
624/2908 3 OR 1.09 (0.84-1.42) 0.520 0.20-5.96 1.09 (0.84-1.42) 0.520 
Takeda, 
201491 
α-carotene 
intake 
High intake 
vs. Low intake 
677/124268 3 OR 0.84 (0.59-1.18) 0.313 0.04-16.60 0.84 (0.64-1.11) 0.221 
Takeda, 
201491 
β-carotene 
intake 
High intake 
vs. Low intake 
1395/125430 6 OR 0.92 (0.70-1.20) 0.521 0.46-1.81 0.92 (0.75-1.13) 0.417 
Takeda, 
201491 
β-
cryptoxanthi
n intake 
High intake 
vs. Low intake 
677/124268 3 OR 0.96 (0.66-1.40) 0.834 0.02-39.43 0.90 (0.69-1.16) 0.411 
Wang, 
201492 
Carbohydrat
e intake 
High intake 
vs. Low intake 
1482/231387 8 RR 1.24 (1.05-1.48) 0.014 1.00-1.54 1.24 (1.05-1.48) 0.014 
Wang, 
201492 
Cholesterol 
intake 
High intake 
vs. Low intake 
1293/168218 7 RR 0.97 (0.75-1.26) 0.833 0.46-2.07 0.91 (0.79-1.05) 0.211 
Wang, 
201492 
Energy 
intake 
High intake 
vs. Low intake 
1415/168643 8 RR 1.39 (1.01-1.92) 0.042 0.50-3.90 0.99 (0.95-1.03) 0.607 
Wang, 
201492 
Protein 
intake 
High intake 
vs. Low intake 
1570/356257 7 RR 1.13 (0.88-1.44) 0.339 0.65-1.97 1.15 (0.95-1.39) 0.151 
Wang, 
201492 
Total fat 
intake 
High intake 
vs. Low intake 
2516/370628 13 RR 0.88 (0.74-1.06) 0.182 0.56-1.40 0.86 (0.75-0.98) 0.024 
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Medical history and comorbid diseases 
Cereda, 
201124 and 
Lu, 201425 
Diabetes 
mellitus 
Diseased vs. 
Non diseased 
10743/54709 6 OR 1.13 (0.73-1.76) 0.591 0.42-3.03 1.24 (0.93-1.65) 0.143 
Jafari, 
201357 
Head injury Exposed vs. 
Non exposed 
35799/17264
7 
22 OR 1.55 (1.33-1.81) 2.2 × 10-8 0.93-2.58 1.56 (1.45-1.67) 3.5 × 10-35 
Liu, 201193 Melanoma Diseased vs. 
Non diseased 
10743/54709 6 OR 1.13 (0.73-1.76) 0.591 0.42-3.03 1.24 (0.93-1.65) 0.143 
Noyce, 
201223 
Anxiety or 
Depression 
Diseased vs. 
Non diseased 
16211/16396
57 
13 RR 1.86 (1.64-2.10) 2.6 × 10-22 1.30-2.66 1.84 (1.78-1.91) 5.8 × 10-258 
Noyce, 
201223 
Cancer Diseased vs. 
Non diseased 
9693/34173 7 RR 0.89 (0.72-1.10) 0.265 0.51-1.53 1.01 (0.94-1.09) 0.777 
Noyce, 
201223 
Constipation Diseased vs. 
Non diseased 
292/6890 2 RR 2.34 (1.55-3.53) 5.5 × 10-5 NE 2.34 (1.55-3.53) 5.5 × 10
-5 
Noyce, 
201223 
Gastric ulcer Diseased vs. 
Non diseased 
406/661 3 RR 1.37 (0.36-5.31) 0.646 1.4 × 10-7–
1.4 × 107 
0.81 (0.49-1.34) 0.413 
Noyce, 
201223 
Hypertensio
n 
Diseased vs. 
Non diseased 
5993/187226 12 RR 0.75 (0.61-0.90) 0.003 0.40- 1.40 0.81 (0.75-0.87) 3.2 × 10-8 
Noyce, 
201223 
Oophorecto
my 
Yes vs. No 775/122149 5 RR 0.77 (0.52-1.13) 0.180 0.23- 2.60 0.76 (0.61-0.94) 0.011 
Shen, 201326 Gout Diseased vs. 
Non diseased 
2234/72909 2 OR 0.70 (0.60-0.82) 5.1 × 10-6 NE 0.70 (0.60-0.82) 5.1 × 10-6 
Drugs 
Gagne, 
201094 
Aspirin Exposed vs. 
Non exposed 
2781/296525 6 RR 1.08 (0.93-1.27) 0.315 0.71-1.66 1.12 (1.01-1.24) 0.027 
Gagne, 
201094 
Non-aspirin 
NSAIDs 
Exposed vs. 
Non exposed 
3967/297453 7 RR 0.85 (0.77-0.94) 0.002 0.74-0.97 0.85 (0.77-0.94) 0.002 
Gao, 201176 Acetaminop
hen 
Exposed vs. 
Non exposed 
2086/295660 4 RR 1.09 (0.96-1.24) 0.192 0.82-1.45 1.09 (0.96-1.24) 0.192 
Gao, 201176 Ibuprofen 
use 
Exposed vs. 
Non exposed 
2170/296165 5 RR 0.73 (0.62-0.85) 6.6 × 10-5 0.57-0.94 0.73 (0.62-0.85) 6.6 × 10-5 
Noyce, 
201223 
Beta-
blockers 
Exposed vs. 
Non exposed 
5774/13671 3 RR 1.28 (1.19-1.39) 5.0 × 10-10 0.77-2.13 1.28 (1.19-1.39) 5.0 × 10-10 
Lang, 201595 Calcium 
channel 
Exposed vs. 
Non exposed 
6966/274947
5 
5 RR 0.78 (0.67-0.90) 7.0 × 10-4 0.55-1.11 0.76 (0.68-0.84) 1.4 × 10-7 
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blockers 
Noyce, 
201223 
General 
anesthesia 
Exposed vs. 
Non exposed 
1571/3110 6 RR 1.10 (0.77-1.58) 0.601 0.35-3.51 0.93 (0.80-1.09) 0.364 
Noyce, 
201223 
Oral 
contraceptiv
es 
Exposed vs. 
Non exposed 
572/121946 3 RR 0.73 (0.43-1.25) 0.250 0.002-346 0.86 (0.68-1.09) 0.215 
Undela, 
201396 
Statins Exposed vs. 
Non exposed 
15102/26188
36 
8 RR 0.77 (0.64-0.92) 0.004 0.47-1.27 0.86 (0.79-0.94) 0.001 
Wang, 
201497 
Hormone 
Replacement 
Therapy 
Exposed vs. 
Non exposed 
4035/808830 14 RR 1.00 (0.84-1.20) 0.967 0.61-1.64 1.10 (1.00-1.22) 0.064 
Biomarkers 
Chen, 201498 BMI BMI≥ 30 vs. 
BMI< 25 
1668/388253
5 
7 OR 0.96 (0.61-1.50) 0.854 0.20-4.62 1.15 (1.01-1.31) 0.040 
Chen, 201498 BMI BMI≥ 30 vs. 
25 •BMI< 30 
1618/243008
8 
7 OR 0.83 (0.65-1.07) 0.157 0.37-1.85 0.89 (0.78-1.01) 0.061 
Chen, 201498 BMI 25 •BMI< 30 
vs. BMI<25 
2428/505848
4 
7 OR 1.20 (0.94-1.53) 0.148 0.53-2.69 1.28 (1.18-1.40) 1.3 × 10
-8 
Gao, 201452 α-synuclein 
in CSF 
High vs. Low 
values 
850/589 11 OR 0.29 (0.13-0.62) 0.002 0.02-5.19 0.48 (0.38-0.59) 4.9 × 10
-12 
Gudala, 
201399 
Serum 
cholesterol 
High vs. Low 
values 
5488/240624 8 RR 0.91 (0.71-1.15) 0.418 0.44-1.86 1.00 (0.90-1.12) 0.985 
Lv, 201451 Serum 
vitamin D 
High vs. Low 
values 
1008/4536 7 OR 0.16 (0.05-0.50) 0.002 0.003-
10.09 
0.40 (0.34-0.47) 9.0 × 10-29 
Mariani, 
201356 
Copper in 
plasma 
High vs. Low 
values 
202/239 4 OR 1.41 (0.03-59.27) 0.856 1.7 × 10-8–
1.2 × 108 
3.47 (2.29-5.24) 3.6 × 10-9 
Mariani, 
201356 
Copper in 
CSF 
High vs. Low 
values 
215/119 5 OR 2.06 (0.57-7.44) 0.271 0.02-207.2 1.70 (1.06-2.75) 0.029 
Mariani, 
201356 
Serum 
copper 
High vs. Low 
values 
425/333 9 OR 1.46 (0.46-4.63) 0.519 0.02-94.65 1.47 (1.08-1.99) 0.013 
Mariani, 
201356 
Iron in CSF High vs. Low 
values 
215/119 5 OR 0.93 (0.35-2.45) 0.887 0.03-30.86 0.86 (0.56-1.32) 0.494 
Mariani, 
201356 
Serum iron High vs. Low 
values 
520/711 10 OR 0.45 (0.17-1.17) 0.102 0.01-16.71 0.41 (0.32-0.51) 2.5 × 10
-14 
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Sako, 
2014100 
Nigral 
volume loss 
High vs. Low 
values 
193/172 8 OR 0.31 (0.17-0.55) 8.3 × 10-5 0.06-1.46 0.30 (0.20-0.44) 1.6 × 10-9 
Shen, 201326 Serum urate High vs. Low 
values 
594/32591 6 RR 0.65 (0.43-0.97) 0.034 0.23-1.82 0.68 (0.50-0.91) 0.009 
Shen, 201355 Serum uric 
acid 
High vs. Low 
values 
1217/1276 6 OR 0.39 (0.27-0.57) 6.8 × 10-7 0.13-1.22 0.33 (0.29-0.38) 1.1 × 10-49 
Yu, 201454 RNFLT High vs. Low 
values 
644/604 13 OR 0.40 (0.24-0.66) 3.5 × 10-4 0.06-2.55 0.39 (0.32-0.49) 1.7 × 10-18 
Zhao, 201353 BMD in 
femoral neck 
High vs. Low 
values 
561/8800 8 OR 0.25 (0.09-0.66) 0.005 0.01-8.76 0.36 (0.30-0.44) 3.4 × 10-24 
Zhao, 201353 BMD in hip High vs. Low 
values 
401/8654 6 OR 0.55 (0.38-0.80) 0.002 0.18-1.66 0.60 (0.49-0.75) 3.2 × 10
-6 
Zhao, 201353 BMD in 
lumbar spine 
High vs. Low 
values 
611/962 9 OR 0.29 (0.16-0.54) 7.8 × 10-5 0.03-2.60 0.30 (0.25-0.37) 1.4 × 10
-32 
Zhao, 201353 BMD in 
trochanter 
High vs. Low 
values 
249/550 4 OR 0.73 (0.48-1.11) 0.146 0.16-3.34 0.75 (0.57-0.99) 0.044 
 
BMD: bone mineral density, BMI: body mass index, CI: confidence interval, CSF: cerebrospinal fluid, HR: hazard ratio, NSAIDs: non-steroidal 
anti-inflammatory drugs, NE: not estimable, OR: odds ratio, PI: prediction interval, RR: risk ratio, RNFLT: retinal nerve fiber layer thickness  
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Table 2. Bias assessment of the 66 eligible meta-analyses of environmental risk factors for Parkinson’s disease. 
 
Reference Risk factor Effect 
size 
Largest study I
2
 Egger test 
p-value 
Observed 
significant 
studies 
Expected 
significant 
studies 
Excess 
significance 
test p-value 
Effect size (95% 
CI) 
SE 
Habits 
Zhang, 201485 Alcohol intake RR 1.01 (0.83-1.23) 0.100 52.3 0.060 7 1.65 2.0 × 10-5 
Noyce, 201223 Coffee drinking RR 0.85 (0.70-1.03) 0.099 42.9 0.002 8 1.66 2.6 × 10-7 
Noyce, 201223 Smoking RR 0.74 (0.67-0.82) 0.052 49.6 0.018 39 10.50 < 1.0 × 10-8 
Li, 201286 Tea drinking OR 0.91 (0.73-1.12) 0.110 53.0 0.758 2 0.46 0.019 
Yang, 201558 Physical activity HR 0.68 (0.51-0.90) 0.145 0 0.556 4 1.83 0.072 
Exposure to toxic environmental agents 
Mortimer, 201287 Manganese exposure RR 0.92 (0.64-1.32) 0.185 62 0.935 1 0.19 0.053 
Mortimer, 201287 Welding RR 0.85 (0.77-0.94) 0.051 0 0.221 2 1.52 0.670 
Palin, 201588 Hydrocarbon exposure OR 1.06 (0.86-1.30) 0.105 28.1 0.020 5 0.75 4.5 × 10-7 
Pezzoli, 201321 Farming RR 1.32 (1.11-1.57) 0.087 37.3 0.219 10 5.18 0.022 
Pezzoli, 201321 Organic solvents RR 1.06 (0.86-1.30) 0.105 43.6 0.024 3 0.96 0.032 
van der Mark, 
201222 
Pesticides RR 1.11 (0.89-1.38) 0.112 63.7 0.057 17 2.27 < 1.0 × 10-8 
Pezzoli, 201321 Rural living RR 1.00 (0.99-1.01) 0.005 78.6 0.001 9 1.55 < 1.0 × 10-8 
Noyce, 201223 Well water drinking RR 1.23 (0.99-1.52) 0.107 70.6 0.005* 10 2.26 < 1.0 × 10-8 
Dietary factors 
Etminan, 200589 Vitamin C intake OR 0.78 (0.61-1.01) 0.129 38.1 0.165 0 0.72 NP 
Etminan, 200589 Vitamin E intake OR 0.69 (0.49-0.98) 0.177 0 0.264 1 0.92 0.926 
Jiang, 201490 Dairy products intake RR 1.33 (1.07-1.65) 0.110 8.2 0.615 4 0.95 7.7 × 10-4 
Takeda, 201491 Lutein intake OR 0.78 (0.56-1.09) 0.170 77.8 0.096 2 0.47 0.018 
Takeda, 201491 Lycopene intake OR 0.87 (0.63-1.20) 0.164 62.3 0.983 1 0.22 0.085 
Takeda, 201491 Vitamin A intake OR 1.16 (0.85-1.58) 0.158 0 0.444 0 0.22 NP 
Takeda, 201491 α-carotene intake OR 0.91 (0.64-1.29) 0.179 22.9 0.847 0 0.18 NP 
Takeda, 201491 β-carotene intake OR 0.90 (0.63-1.29) 0.183 37.5 0.862 1 0.37 0.286 
Takeda, 201491 β-cryptoxanthin intake OR 0.74 (0.53-1.03) 0.169 42.1 0.271 0 0.49 NP 
Wang, 201492 Carbohydrate intake RR 1.29 (0.98-1.70) 0.141 0 0.613 1 0.91 0.917 
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Wang, 201492 Cholesterol intake RR 0.87 (0.69-1.10) 0.119 62.4 0.273 2 0.48 0.022 
Wang, 201492 Energy intake RR 0.97 (0.93-1.02) 0.024 83.8 0.084 2 0.41 0.010 
Wang, 201492 Protein intake RR 1.60 (1.10-2.20) 0.177 30.4 0.676 1 2.32 NP 
Wang, 201492 Total fat intake RR 0.69 (0.52-0.91) 0.143 34.4 0.070* 2 2.52 NP 
Medical history and comorbid diseases 
Cereda, 201124 
and Lu, 201425 
Diabetes mellitus OR 1.41 (1.20-1.66) 0.083 78.1 0.035* 9 6.74 0.270 
Jafari, 201357 Head injury OR 1.94 (1.69-2.23) 0.071 61 0.569 10 8.58 0.533 
Liu, 201193 Melanoma OR 1.44 (1.03-2.01) 0.171 24.1 0.718 1 2.77 NP 
Noyce, 201223 Anxiety or Depression RR 1.79 (1.72-1.86) 0.020 67.7 0.755 10 7.3 0.132 
Noyce, 201223 Cancer RR 1.04 (0.96-1.12) 0.039 50.4 0.132 1 0.43 0.364 
Noyce, 201223 Constipation RR 2.18 (1.32-3.61) 0.257 0 NE 2 0.9 0.116 
Noyce, 201223 Gastric ulcer RR 0.47 (0.25-0.84) 0.309 81 0.072* 2 1.04 0.243 
Noyce, 201223 Hypertension RR 0.96 (0.80-1.15) 0.093 76.4 0.392 5 0.64 2.0 × 10-8 
Noyce, 201223 Oophorectomy RR 0.75 (0.56-0.99) 0.145 58.8 0.931 2 0.55 0.039 
Shen, 201326 Gout RR 0.70 (0.59-0.83) 0.087 0 NE 2 1.56 0.452 
Drugs 
Gagne, 201094 Aspirin RR 1.13 (0.96-1.33) 0.083 50.3 0.335 1 0.53 0.497 
Gagne, 201094 Non-aspirin NSAIDs RR 0.93 (0.80-1.08) 0.077 0.1 0.034 1 0.45 0.393 
Gao, 201176 Acetaminophen RR 1.16 (1.00-1.35) 0.077 0 0.058* 0 0.48 NP 
Gao, 201176 Ibuprofen RR 0.77 (0.61-0.98) 0.121 0 0.588 3 1.12 0.044 
Noyce, 201223 Beta-blockers RR 1.28 (1.16-1.41) 0.050 0 0.403 2 1.48 0.546 
Lang, 201595 Calcium channel blockers RR 0.70 (0.61-0.81) 0.074 25.7 0.128 2 2.03 NP 
Noyce, 201223 General anesthesia RR 0.74 (0.61-0.91) 0.102 74.2 0.195 2 0.92 0.223 
Noyce, 201223 Oral contraceptives RR 1.02 (0.77-1.36) 0.145 71.1 0.390 1 0.15 0.025 
Undela, 201396 Statins RR 0.94 (0.82-1.09) 0.073 62.9 0.015 2 0.7 0.105 
Wang, 201597 Hormone Replacement Therapy RR 1.21 (1.00-1.46) 0.097 50.4 0.013* 4 1.45 0.025 
Biomarkers 
Chen, 201498 BMI  
(BMI≥ 30 vs. BMI< 25) 
OR 2.34 (1.83-2.97) 0.124 90.6 0.189 2 4.94 NP 
Chen, 201498 BMI  
(BMI≥ 30 vs. 25 •BMI< 30) 
OR 1.20 (0.96-1.50) 0.114 71.5 0.319 3 0.68 0.003 
Chen, 201498 BMI 
(25 •BMI< 30 vs. BMI<25) 
OR 1.16 (0.99-1.37) 0.083 85.2 0.541 2 0.67 0.088 
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Gao, 201452 α-synuclein in CSF OR 1.17 (0.75-1.84) 0.230 91.7 0.120 7 0.60 < 1.0 × 10-8 
Gudala, 201399 Serum cholesterol RR 1.06 (0.88-1.26) 0.092 70.3 0.234 2 0.48 0.023 
Lv, 201451 Serum vitamin D OR 0.73 (0.55-0.96) 0.142 97.7 0.063 7 0.71 < 1.0 × 10-8 
Mariani, 201356 Copper in plasma OR 85.10 (44.70-
162.02) 
0.329 98.7 0.272 3 3.96 NP 
Mariani, 201356 Copper in CSF OR 0.91 (0.40-2.08) 0.421 83.8 0.680 2 0.25 3.8 × 10-4 
Mariani, 201356 Serum copper OR 0.66 (0.32-1.35) 0.366 92.6 0.913 4 0.63 1.0 × 10-5 
Mariani, 201356 Iron in CSF OR 0.64 (0.28-1.45) 0.421 79.8 0.487 2 0.34 3.2 × 10-3 
Mariani, 201356 Serum iron OR 0.16 (0.11-0.24) 0.204 93.6 0.615 7 5.14 0.240 
Sako, 2014100 Nigral volume loss OR 0.22 (0.11-0.42) 0.333 47.4 0.917 3 1.74 0.280 
Shen, 201326 Serum urate RR 0.60 (0.30-1.10) 0.331 42.1 0.390 2 1.37 0.556 
Shen, 201355 Serum uric acid OR 0.23 (0.19-0.29) 0.111 75.9 0.286 4 3.74 0.830 
Yu, 201454 RNFLT OR 0.58 (0.35-0.95) 0.258 81 0.969 8 1.26 < 1.0 × 10-8 
Zhao, 201353 BMD in femoral neck OR 0.47 (0.31-0.71) 0.213 95.6 0.267 5 1.81 0.007 
Zhao, 201353 BMD in hip OR 0.95 (0.62-1.44) 0.213 61.8 0.192 4 0.30 < 1.0 × 10-8 
Zhao, 201353 BMD in lumbar spine OR 0.90 (0.59-1.37) 0.217 89 0.747 6 0.48 < 1.0 × 10-8 
Zhao, 201353 BMD in trochanter OR 0.86 (0.57-1.31) 0.213 45.6 0.733 1 0.22 0.090 
BMD: bone mineral density, BMI: body mass index, CI: confidence interval, CSF: cerebrospinal fluid, HR: hazard ratio, NSAIDs: non-steroidal 
anti-inflammatory drugs, NE: not estimable, OR: odds ratio, PI: prediction interval RR: risk ratio, RNFLT: retinal nerve fiber layer thickness  
*In the annotated papers, the Egger test was statistically significant (p<0.10) but the largest study has larger effect size compared to the summary 
effect size under random effects, denoting the absence of small-study effects 
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Table 3. Assessment across the 66 associations of environmental risk factors with Parkinson’s disease 
Association does NOT imply causation. See Discussion for alternative explanations for convincing and suggestive associations.  
Risk factors Sample size 
(number of 
cases) 
Estimate of 
heterogeneity 
95% prediction 
interval 
Small-study effect or 
excess significance 
bias 
Random effects 
summary effect size 
(95% CI) 
Significance threshold 
reached (under the random-
effects model) 
Associations supported by highly suggestive evidence  
Anxiety or depression23 >1000 Large Excluding the null value Neither 1.86 (1.64-2.10) <10-6 
Beta-blockers23 >1000 Not large Including the null value Neither 1.28 (1.19-1.39) <10-6 
Head injury57 >1000 Large Including the null value Neither 1.55 (1.33-1.81) <10-6 
Physical activity58 >1000 Not large Excluding the null value Excess significance bias 0.66 (0.57-0.78) <10-6 
Serum uric acid55 >1000 Very large Including the null value Neither 0.39 (0.27-0.57) <10-6 
Smoking23 >1000 Not large Excluding the null value Both 0.64 (0.60-0.69) <10-6 
Associations supported by suggestive evidence  
Alcohol intake85 >1000 Large Including the null value Both 0.75 (0.66-0.85) <0.001 but >10-6 
Calcium channel 
blockers95 
>1000 Not large Including the null value Neither 0.78 (0.67-0.90) <0.001 but >10-6 
Coffee drinking23 >1000 Not large Excluding the null value Both 0.67 (0.58-0.76) <10-6 
Dairy products intake90 >1000 Not large Excluding the null value Excess significance bias 1.40 (1.20-1.63) <0.001 but >10-6 
Farming21 >1000 Not large Including the null value Excess significance bias 1.30 (1.16-1.46) <0.001 but >10-6 
Ibuprofen76 >1000 Not large Excluding the null value Excess significance bias 0.73 (0.62-0.85) <0.001 but >10-6 
Pesticides22 >1000 Large Including the null value Both 1.62 (1.40-1.88) <10-6 
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Rural living21 >1000 Very Large Including the null value Both 1.32 (1.18-1.48) <0.001 but >10-6 
Welding87 >1000 Not large Excluding the null value Neither 0.86 (0.80-0.92) <0.001 but >10-6 
Associations supported by weak evidence 
BMD in femoral neck53 >500 but 
<1000 
Very large Including the null value Excess significance bias 0.25 (0.09-0.66) <0.05 but >0.001 
BMD in hip53 <500 Large Including the null value Excess significance bias 0.55 (0.38-0.80) <0.05 but >0.001 
BMD in lumbar spine53 >500 but 
<1000 
Very large Including the null value Excess significance bias 0.29 (0.16-0.54) <0.05 but >0.001 
Carbohydrate intake92 >1000 Not large Excluding the null value Neither 1.24 (1.05-1.48) <0.05 but >0.001 
Energy intake92 >1000 Very large Including the null value Both 1.39 (1.01-1.92) <0.05 but >0.001 
Hydrocarbon exposure88 >1000 Not large Including the null value Both 1.36 (1.13-1.63) <0.05 but >0.001 
Hypertension23 >1000 Very large Including the null value Excess significance bias 0.75 (0.61-0.90) <0.05 but >0.001 
Nigral volume loss100 <500 Not large Including the null value Neither 0.31 (0.17-0.55) <0.05 but >0.001 
Non asprin NSAIDs94 >1000 Not large Excluding the null value Small-study effects 0.85 (0.77-0.94) <0.05 but >0.001 
Organic solvents21 >1000 Not large Excluding the null value Both 1.22 (1.01-1.47) <0.05 but >0.001 
RNFLT54 >500 but 
<1000 
Very large Including the null value Excess significance bias 0.40 (0.24-0.66) <0.05 but >0.001 
Serum urate26 >500 but 
<1000 
Not large Including the null value Neither 0.65 (0.43-0.97) <0.05 but >0.001 
Serum vitamin D51 >1000 Very large Including the null value Both 0.16 (0.05-0.50) <0.05 but >0.001 
Statins96 >1000 Large Including the null value Small study effects 0.77 (0.64-0.92) <0.05 but >0.001 
Vitamin E intake89 >500 but 
<1000 
Not large Including the null value Neither 0.81 (0.67-0.98) <0.05 but >0.001 
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Well water drinking23 >1000 Large Including the null value Excess significance bias 1.21 (1.05-1.40) <0.05 but >0.001 
α-synuclein in CSF52 >500 but 
<1000 
Very large Including the null value Excess significance bias 0.29 (0.13-0.62) <0.05 but >0.001 
Associations not adequately assessed owing to small number of studies 
Constipation23 <500 Not large NA NA 2.34 (1.55-3.53) <0.001 
Gout26 >1000 Not large NA NA 0.70 (0.60-0.82) <0.001 
Not significant associations 
Acetaminophen intake76 >1000 Not large Including the null value Neither 1.09 (0.96-1.24) >0.05 
Aspirin intake94 >1000 Large Including the null value Neither 1.08 (0.93-1.27) >0.05 
BMD in trochanter53 <500 Not large Including the null value Neither 0.73 (0.48-1.11) >0.05 
BMI  
(BMI≥ 30 vs. BMI< 
25)98 
>1000 Very large Including the null value Neither 0.96 (0.61-1.50) >0.05 
BMI  
(BMI≥ 30 vs. 25 •BMI< 
30)98 
>1000 Large Including the null value Excess significance bias 0.83 (0.65-1.07) >0.05 
BMI 
(25 •BMI< 30 vs. 
BMI<25)98 
>1000 Very large Including the null value Excess significance bias 1.20 (0.94-1.53) >0.05 
Cancer23 >1000 Large Including the null value Neither 0.89 (0.72-1.10) >0.05 
Cholesterol intake92 >1000 Large Including the null value Excess significance bias 0.97 (0.75-1.26) >0.05 
Copper in plasma56 <500 Very large Including the null value Neither 1.41 (0.03-59.27) >0.05 
Copper in CSF56 <500 Very large Including the null value Excess significance bias 2.06 (0.57-7.44) >0.05 
Diabetes mellitus24,25 >1000 Very large Including the null value Neither 0.91 (0.74-1.11) >0.05 
Gastric ulcer23 <500 Very large Including the null value Neither 1.37 (0.36-5.31) >0.05 
General anesthesia23 >1000 Large Including the null value Neither 1.10 (0.77-1.58) >0.05 
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Hormone replacement 
therapy97 
>1000 Large Including the null value Excess significance bias 1 (0.84-1.20) >0.05 
Iron in CSF56 <500 Very large Including the null value Excess significance bias 0.93 (0.35-2.45) >0.05 
Lutein intake91 >500 but 
<1000 
Very large Including the null value Both 1.49 (0.83-2.68) >0.05 
Lycopene intake91 >500 but 
<1000 
Large Including the null value Neither 1.03 (0.64-1.65) >0.05 
Manganese exposure87 >1000 Large Including the null value Neither 0.76 (0.41-1.42) >0.05 
Melanoma93 >1000 Not large Including the null value Neither 1.13 (0.73-1.76) >0.05 
Oophorectomy23 >500 but 
<1000 
Large Including the null value Excess significance bias 0.77 (0.52-1.13) >0.05 
Oral contraceptives23 >500 but 
<1000 
Large Including the null value Excess significance bias 0.73 (0.43-1.25) >0.05 
Protein intake92 >1000 Not large Including the null value Neither 1.13 (0.88-1.44) >0.05 
Serum cholesterol99 >1000 Large Including the null value Excess significance bias 0.91 (0.71-1.15) >0.05 
Serum copper56 <500 Very large Including the null value Excess significance bias 1.46 (0.46-4.63) >0.05 
Serum iron56 >500 but 
<1000 
Very large Including the null value Neither 0.45 (0.17-1.17) >0.05 
Tea intake86 >1000 Large Including the null value Excess significance bias 0.86 (0.68-1.08) >0.05 
Total fat intake92 >1000 Not large Including the null value Neither 0.88 (0.74-1.06) >0.05 
Vitamin A intake91 >500 but 
<1000 
Not large Including the null value Neither 1.09 (0.84-1.42) >0.05 
Vitamin C intake89 >1000 Not large Including the null value Neither 1.06 (0.86-1.30) >0.05 
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α-carotene intake91 >500 but 
<1000 
Not large Including the null value Neither 0.84 (0.59-1.18) >0.05 
β-carotene intake91 >1000 Not large Including the null value Neither 0.92 (0.70-1.20) >0.05 
β-cryptoxanthin intake91 >500 but 
<1000 
Not large Including the null value Neither 0.96 (0.66-1.40) >0.05 
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Table 4. Quality assessments of primary studies. 13 papers assessed the quality of the primary observational studies using the Newcastle 
Ottawa Scale (NOS). Two additional papers used different methods to assess the included studies (criteria set by authors in the case of Cereda 
2011 and QUADAS-2 in the case of Gao 2014). The other 18 papers did not perform any quality assessment. 
Reference Risk factor High quality  
(NOS score = 9) 
Moderate quality  
(NOS score = 7 or 8) 
Low quality  
(NOS score < 7) 
Gagne, 201094 
Aspirin 0  6 0 
Non-aspirin NSAIDs 0  7 0 
Gudala, 201399 Serum cholesterol 3 1 4 
Jafari, 201357 Head injury 6 7 9 
Lang, 2015* Calcium channel blockers 0 5 0 
Lu, 201425 Diabetes mellitus 0 6 8 
Lv, 201451 Serum vitamin D 2 5 0 
Pezzoli, 201321 
Farming 0 16 21 
Organic solvents 0 7 11 
Rural living 0 4 27 
Shen, 201326 * 
Serum urate 0 6 0 
Gout 0 2 0 
Takeda, 201491 
Lutein intake 0 3 1 
Lycopene intake 0 2 1 
Vitamin A intake 0 2 1 
α-carotene intake 0 1 2 
β-carotene intake 0 3 3 
β-cryptoxanthin intake 0 1 2 
Undela, 201396 Statins 1 5 2 
Wang, 201597 Hormone replacement therapy 0 6 8 
Yu, 201454 * RNFLT 0 11 2 
Zhang, 201485 Alcohol 0 12 21 
 
*These papers used as a threshold for moderate quality a NOS score=6 
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